Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CAFs (Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC): a Phase I/II Study

NCT04467723 is registered in ClinicalTrials.gov with University of Kansas Medical Center as lead sponsor.

NCT NCT04467723
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04467723 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CAFs (Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC): a Phase I/II Study
Lead sponsor
University of Kansas Medical Center
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 18, 2022
Completion date
August 31, 2027
Enrollment
25 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc stage iv, nsclc, recurrent